TP53 and colorectal carcinoma: In this study, we showed that PTEN-deficient CRC cells exhibited much higher fold-increase in p53 level upon MDM2 inhibitor treatment, and such a differential activation of p53 could provide the differential sensitivity of CRC cells to MDM2 inhibitor.